Latest News

Intranasal ketamine confers rapid antidepressant effect in depression

The first controlled evidence has been released showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect ?- within 24 hours ?- and was well tolerated in patients with treatment-resistant major depressive disorder. One of the most common NMDA receptor antagonists, ketamine is an FDA-approved anesthetic. It has been used in animals and humans for years. Ketamine has also been a drug of abuse and can lead to untoward psychiatric or cognitive problems when misused. In low doses, ketamine shows promise in providing rapid relief of depression, with tolerable side effects.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Altered pain processing in patients with cognitive impairment

  • ONT-380 has stage IV HER2+ breast cancer patient 'worrying about normal stuff again'

  • Social work researchers create easier, accurate way to analyze TSCC trauma results

  • Alzheimer's culprit causes memory loss even before brain degeneration

  • A patient's budding cortex -- in a dish? Networking neurons thrive in 3-D human 'organoid'

  • Vision: Deciphering dark and bright

  • Promising trial results of brigatinib show that all next-gen ALK inhibitors may not be created equal

  • Brain training induces lasting brain, mental health gains for veterans, civilians with brain injury

  • Researchers unravel a link between a genetic mutation and autistic behaviors, then find a way to undo it

  • Scientists retrieve lost memories using optogenetics

  •